Skip to main content

Table 7 Treatment-related outcomes most important to patients with or at risk for AD and care partners

From: Assessing what matters most to patients with or at risk for Alzheimer’s and care partners: a qualitative study evaluating symptoms, impacts, and outcomes

Ideal treatment outcome, n (%)

AD classification

Total (N = 60)

Group 1 (n = 12)

Group 2 (n = 12)

Group 3 (n = 12)

Group 4 (n = 12)

Group 5 (n = 12)

Improve/restore memory

9 (75.0)

7 (58.3)

5 (41.7)

9 (75.0)

10 (83.3)

40 (66.7)

Stop AD progression

8 (66.7)

6 (50.0)

7 (58.3)

7 (58.3)

7 (58.3)

35 (58.3)

Slow AD progression

4 (33.3)

6 (50.0)

3 (25.0)

5 (41.7)

2 (16.7)

20 (33.3)

Improve ability to function, perform ADLs

4 (33.3)

0 (0.0)

1 (8.3)

5 (41.7)

5 (41.7)

15 (25.0)

Improve short-term memory

3 (25.0)

3 (25.0)

3 (25.0)

3 (25.0)

2 (16.7)

14 (23.3)

Remember family

5 (41.7)

0 (0.0)

2 (16.7)

3 (25.0)

2 (16.7)

12 (20.0)

Cure AD

1 (8.3)

3 (25.0)

1 (8.3)

3 (25.0)

3 (25.0)

11 (18.3)

Help remain independent, not be a burden

1 (8.3)

0 (0.0)

0 (0.0)

2 (16.7)

3 (25.0)

6 (10.0)

Remove plaque/tangles/stop growth

2 (16.7)

0 (0.0)

1 (8.3)

0 (0.0)

3 (25.0)

6 (10.0)

Be sharper, more focused

0 (0.0)

3 (25.0)

0 (0.0)

1 (8.3)

1 (8.3)

5 (8.3)

Be aware of self and surroundings

0 (0.0)

0 (0.0)

0 (0.0)

1 (8.3)

3 (25.0)

4 (6.7)

Improve long-term memory

1 (8.3)

0 (0.0)

0 (0.0)

2 (16.7)

0 (0.0)

3 (5.0)

Stop hallucinations

0 (0.0)

0 (0.0)

0 (0.0)

1 (8.3)

0 (0.0)

1 (1.7)

  1. AD Alzheimer’s disease, ADLs activities of daily living
  2. Note: Participants were allowed to report multiple treatment outcomes; thus, the sums exceed 100%. Data shown are the number and percentage of individuals endorsing an outcome in each group and overall. Information was collected from patients only from groups 1, 2, and 3; from care partners and patients (when able to self-report) in group 4; and from care partners only in group 5